Carelink and Monsenso partner to deliver digitally enabled nationwide mental health services

Carelink and Monsenso partner to deliver digitally enabled nationwide mental health services

by | Dec 14, 2023 | ADHD, Anxiety, Children and Adolescents, Depression, Eating Disorders, Mental Illness, News

Carelink Nærhospital and Monsenso entered into a partnership and expect to deliver the first digitally supported mental health services in January 2024. 

Carelink Group, Denmark’s largest private health and welfare services group, and Monsenso, a leading provider of validated digital mental health solutions, have entered into a groundbreaking partnership that will redefine the way mental health services are delivered for the benefit of patients, healthcare professionals, and the healthcare sector as a whole.

Mental health is a crucial part of our society, and the need for innovative solutions to address challenges in this area has never been bigger. Carelink’s extensive experience in delivering high-quality healthcare services, combined with Monsenso’s advanced digital health solution, has the potential to create lasting value for both the healthcare sector, the work of healthcare professionals, and particularly for patients. The partnership aligns with the Danish government’s initiatives in psychiatry and the recently presented Finance Act for 2024.

Key points in this partnership include:

  1. Highly scalable digitally supported healthcare services: The partnership creates an innovative foundation that integrates traditional mental health services with advanced digital solutions. This comprehensive offering will provide individual users with tools for digital self-help, self-monitoring and effective remote clinician follow-up before, during, and after treatment.
  2. Addressing workforce issues: The shortage of qualified personnel in mental health is a challenge. This partnership aims to alleviate the problem by optimising resources and leveraging technology to expand the reach of healthcare professionals, enabling them to serve a larger number of patients.
  3. Reduced waiting times: Long waiting lists for mental health services are a significant problem nationwide. The collaboration will streamline the process and offer timely assistance through a combination of digital solutions and remote follow-up, ensuring that patients receive the support they need promptly.
  4. Improved patient experience: Patients will experience a more patient-centered and convenient approach to assessment and treatment for mental disorders. The partnership will enhance the patient experience, promote patient involvement, and provide effective follow-up, support, and treatment.
  5. Quality treatment: The combined offering will promote better treatment outcomes, as patients will have the necessary tools and support for digital self-help, self-monitoring, and effective remote follow-up. This is expected to lead to improved quality of life, more efficient processes, and a reduction in relapses.

“We have entered into this partnership to meet the pressure on psychiatry and the healthcare sector today. We aim to create a Digital First but not Digital Only offering, making waiting lists, assessment, and treatment processes more patient-centric. We believe we can achieve this by leveraging the latest clinically validated technologies to effectively follow up on treatment – also at a distance and in patients’ own homes,” says Maria Pico Almsgaard, CEO of Carelink Nærhospital.

“The potential in the partnership to create easily accessible, nationwide offerings is significant. Far too many patients are waiting for treatment and not provided with the effective, digitally supported offerings that they would like. Better assistance for children and young people, as well as digital offerings, is a priority for the government, and that’s why we have also started with digitally supported offerings for children and young people, but with new pathways continuously added,” says Thomas Lethenborg, CEO of Monsenso.

Click the button below for more information about the Monsenso solution.

Solution
Artificial intelligence creates individually tailored treatment for depression

Artificial intelligence creates individually tailored treatment for depression

by | Mar 28, 2023 | Depression, News, Research Projects

A new innovation project “Personae” will provide easier access to personalised digital treatment for patients with depression through Monsenso’s digital health platform. The project leverages patient-reported outcomes and AI to screen patients and to deliver a treatment tailored to the individual patients’ needs.

According to the WHO, more than one billion people worldwide have mental disorders, but the number of individuals receiving help is alarmingly low. In Western Europe, for instance, only half of the citizens with anxiety or depression receive relevant treatment. At the same time, the healthcare system is challenged by a shortage of healthcare professionals.

Therefore, Innovation Fund Denmark is funding the development of a personalised treatment based on Monsenso’s digital health solution, which will leverage artificial intelligence to tailor the treatment to the individual patient’s needs.

Today, digital programs provide evidence-based treatment to citizens with depression, for example in the Danish clinic” Internetpsykiatrien”. Research shows that such programs have the same effect on citizens with mild to moderate depression as physical therapy sessions. The potential is huge, with thousands of citizens on waiting lists or receiving no relevant support at all. However, delivering a personalised intervention to everyone is challenging. Some patients benefit from a fully automated, digital treatment program, others need their treatment program supported by a psychologist, and yet other patients with complex life situations need physical meetings with their healthcare providers.

“The project enables us to use artificial intelligence, which, in collaboration with Monsenso’s digital health solution and the Internetpsykiatrien, can ensure that more people can quickly get access to the right treatment. This next generation of digital treatment will make it much easier to offer a fully or partially digital treatment that matches each individual’s needs,” says Kim Mathiasen, research director at the Center for Digital Psychiatry, who leads the Personae project.

”We see great potential in this project. It enables us to continue the development of our digital health solution and further validate it. It will improve the way we use people’s own health and behavioral data to keep them engaged, customise their treatment and support clinical decision-making at scale”, says Thomas Lethenborg, CEO at Monsenso.

”The unique, patient-reported data that will be generated from the screening and continuous use of Monsenso’s solution in Internetpsykiatrien is a fantastic foundation for development, training and validation of algorithms for automatisation of decision support and optimisation of treatment pathways”, says Dr. Pepijn Van de Ven, Senior Lecturer at Limerick University.

The primary ambition of the project is to develop intelligent adaptations of treatment content to match patients’ symptoms and life situations. The solution should be able to identify early signs of drop-out and support patients’ and healthcare providers’ decisions concerning treatment. The artificial intelligence solutions will be incorporated into both the public Internetpsykiatrien clinic, which the Center for Digital Psychiatry operates, and into the digital health solution of Monsenso.

The project is led by the Center for Digital Psychiatry, which, in Danish and international contexts, is a pioneer in internet-based therapy in terms of development, research, and operation. This project combines their research and extensive clinical experience with the competencies and commercial platform of Monsenso, as well as the unique competencies in artificial intelligence for mental health at the University of Limerick. 

Facts
Project title: Personae – Personalised Digital Treatment of Depression
Total budget: DKK 22.1 mio.
Innovation Fund Denmark investment: DKK 16.5 mio.
Net contribution to Monsenso: DKK 3.9 mio.
Duration: 4 years

About the partners
Center for Digital Psychiatry at Region Southern Denmark works to ensure that all Danes have easy and equal access to mental health. In a Danish and international context, the Center for Digital Psychiatry are frontrunners in the use of digital solutions for mental health promotion and psychiatric treatment and they are experts in matching the current needs of psychiatry with the right digital technology.

The University of Limerick, Department of Electronic & Computer Engineering, has high expertise in research and teaching in information and communication technology. The Department of Electronic & Computer Engineering is a leader in research on artificial intelligence for Internet-based therapy.

Odense University Hospital, the Danish Depression Association and the strategic innovation agency Is It a Bird are also involved in the project.

Further information:
Monsenso:
CEO
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com 

Certified Adviser:
Norden CEF A/S
John Norden
Tel. +45 20 72 02 00
E-mail: jn@nordencef.dk

 

BOOK A DEMO
DIPNOT: A Research Project to Improve Psychotherapeutic Treatment for People with Depression

DIPNOT: A Research Project to Improve Psychotherapeutic Treatment for People with Depression

by | Oct 25, 2022 | Depression, Mental Illness, News

Monsenso is proud to be part of the Development of an Intervention for Persistent Not On Track (DIPNOT) research project that aims to improve psychotherapeutic treatment offered to people with depression in psychiatry.

Though often said to be one of the “happiest countries on earth”, depression is no rare illness in Denmark. Did you know, that approximately 15-25% of all females and 7-12% of all males living in Denmark experience depression at least once in their life? [1].

After diagnosis, patients with depression are often offered group-based cognitive behavioural therapy (CBT) in outpatient psychiatry in Denmark [2]. However, around 50% of depressed patients participating in group-based CBT do not actually feel their symptoms improving, or even worsening during the therapy [2].

The DIPNOT research project, which was started in 2021 and continues until 2024, hence aims to design an intervention for patients with depression who are not improving during the course of their therapy. The idea is to monitor patients and the progression of their symptoms via a digital health application (e.g., using clinical questionnaires) and identify the patients who are not doing well during the therapy [2].

The Monsenso digital health solution is currently being used for this purpose in the DIPNOT project conducted by ph.d. student Jasmin Rejaye Gryesten. It facilitates the identification of worsening depressive symptoms and offers various possibilities for clinicians to provide their patients with digital tools that can help their recoveries – such as exercises and psychoeducational content.

At Monsenso, we are proud to be part of this exciting journey toward offering better mental health to more people by being able to cater to patients’ needs more individually.

If you want to learn more about the DIPNOT project, watch this video!
——————————————————————————————————————————-

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com

References:
[1] Kessing, L.V. (2021). ​​Depression, forekomst. Sundhed.dk.
https://www.sundhed.dk/borger/patienthaandbogen/psyke/sygdomme/depression/depression-forekomst/

[2] DIPNOT (n.d.). Development of an Intervention for Persistent Not On Track.
https://www.dipnot.dk

​​

BOOK A DEMO
Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

Monsenso has signed an agreement with Awakn Life Sciences, a global biotech company

by | Nov 9, 2021 | Addiction, Depression, News, Pharma

Monsenso has signed an agreement with, a global biotech company, to support the company’s medical psychedelic treatments. Awakn Life Sciences is a global biotech company that leads the field of psychedelic medicine for the treatment of addiction. In October 2021 commenced the implementation of the Monsenso Digital Health Solution in Awakn Life Sciences clinical practice as a tool for supporting patients throughout their treatment while capturing real-world patient insights to inform clinical decision-making and personalised treatment.

Mental illness and addiction are some of the biggest public health challenges facing the global community.

Nearly one billion people worldwide suffer from mental illness, for which there are too few effective treatments available beyond coping strategies and treating symptoms. With global spending on mental health estimated to reach $16 trillion by 2030 (as measured by lost economic output)[1], it is critical that effective new treatments are developed to address the current gaps. Psychedelic-assisted therapy has emerged as a potential solution to this treatment vacuum. In the early 20th century, these substances were severely restricted and had a negative connotation. Today, however, a growing body of evidence and urgent unmet patient needs have led clinicians and regulators to consider them as a viable treatment option.

Psychedelic-Assisted Psychotherapy represents a paradigm shift in psychiatric treatment

Psychedelic drugs are substances that alter perception and mood and affect various cognitive processes. When used in conjunction with psychotherapy, they can put patients in a temporary state where they can better process memories, emotions, and past traumas[2], allowing for processing that enables subjects to let go of things that have previously troubled them[3]. For the same reason, psychedelic-assisted psychotherapy has shown effective in treating historically difficult-to-treat illnesses[4] and is today considered a promising game-changer in psychiatric treatment[5,6,7].

While psychedelics have spurred great interest in the life science industry, only a few psychedelic companies are currently treating patients in the clinical setting. Awakn Life Sciences launched the UK’s first psychedelic-assisted clinic in Bristol, followed by London and Manchester, offering evidence-based psychedelic therapies for addiction and other mental health indications, and has also opened a clinic in Oslo, Norway with plans to scale across Europe quickly.

In October 2021, Awakn Life Science commenced implementation of the Monsenso Digital Health Solution in its clinical practice to support patients throughout their treatment journey and to capture real-world data to inform clinicians’ decision making for personalised patient support and management.

“We are excited to work with Awakn Life Science to support new treatment options for people who have experienced insufficient treatment results. We look forward to partnering with Awakn Life Sciences and be part of their growth journey” says CEO of Monsenso, Thomas Lethenborg.

Awakn’s CEO, Anthony Tennyson added “There’s such a critical need to provide solutions and hope to people suffering from mental illnesses and addiction. We’re excited to partner with Monsenso to better engage with clients throughout their treatment, gain insights to help inform clinical decisions and improve health outcomes, and generate insights that inform our research and treatment development programs”.

About Awakn Life Sciences 
Awakn Life Sciences is a publicly-traded (NEO: AWKN) (OTCQB: AWKNF) biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of worldleading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies and enabling technologies to treat Addiction.

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Sources:

[1] https://www.weforum.org/agenda/2020/10/mental-health-day-covid19-coronavirus-global/

[2] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[3] Jennifer Mitchell, neuroscientist and professor in the departments of neurology, psychiatry and behavioral sciences at the University of California San Francisco.

[4] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

[5] https://www.health.harvard.edu/blog/back-to-the-future-psychedelic-drugs-in-psychiatry-202106222508

[6] https://www.scientificamerican.com/article/a-renaissance-for-psychedelics-could-fill-a-long-standing-treatment-gap-forpsychiatric-disorders/

[7] Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

BOOK A DEMO
Mental health in an unequal world. World Mental Health Day 2021

Mental health in an unequal world. World Mental Health Day 2021

by | Oct 9, 2021 | Blog, Depression, Mental Illness

Mental illness, why bother if all goes well? Because the day it hits you or your loved ones, you may be faced with the harsh reality of “Mental Health in an unequal world”. Close to 1 billion people globally are living with a mental disorder. Yet, countries spend on avg. 2% of their national health budgets on mental health leaving a disproportionate gap between demand for mental health services and supply. Each year, October 10th marks the “World Mental Health Day”. This year the theme is “Mental Health in an Unequal World”. 

Originally chosen by the World Federation for Mental Health, the theme Mental Health in an Unequal World” refers to the inequality in access to health services in low- and middle-income countries, where between 75% and 95% of patients with mental disorders have no access to mental health services at all. Despite the universal nature and the magnitude of mental illness, the gap between demand for mental health services and supply remains substantial.

The global pandemic along with the climate crisis and social disarrangement lead the world to a difficult place. To date, the pandemic is impacting people of all ages and backgrounds: Illness, economic impact, job insecurity, and most importantly, physical distancing leading to social isolation and millions of people facing mental health issues.

  • Close to one billion people have a mental disorder and anyone can be affected.
  • Depression is a leading cause of disability worldwide and a major contributor to the global burden of disease. Globally, an estimated 5% of adults suffer from depression.
  • Globally, one in seven 10-19-year-olds suffers from a mental disorder. Half of all such disorders begin by the age of 14, but most go undiagnosed and untreated.
  • People with severe mental disorders like schizophrenia typically die 10-20 years earlier than the general population.
  • One in 100 deaths is by suicide. It is the fourth leading cause of death among young people aged 15-29.
  • The COVID -19 pandemic has had a significant impact on people’s mental health.

The World Federation for Mental Health also addresses the disparity between mental health investment and overall health. On average, countries spend only 2% of their national health budgets on mental health. This has changed little in recent years. Despite the scale of mental illness, the gap between demand for mental health services and supply remains substantial. Unaddressed mental health issues are now a leading global cause of disability and suffering. Yet only 10% receive “adequate” treatment – 75% receive no treatment at all.

The limited global availability of effective mental health treatments and a lack of objective measures of response to treatment, are some of the barriers in advancing patient outcomes. To reduce burden, it is critical to diagnose and monitor mood disorders using widely accessible, less costly, and scalable methods, which can enable a higher degree of specificity in mental health diagnoses and timely detection of clinical deterioration.

Building on the widespread adoption of smartphones, mobile health (mhealth) has gained significant interest as a means for capturing continuous, objectively observable and measurable data of patients’ behaviour and mental state. The data collected on smartphones and sensors represent a new approach aimed at measuring human behaviour and mental health, and thus an opportunity of detecting, assessing, and monitoring psychiatric disorders in a less costly and less burdensome way for the clinician.

The data collected on the smartphone are also referred to as digital biomarkers. These can be collected both passively through inbuilt sensors on the smartphone (physical activity and geolocation, social activity, text messages usage, phone usage, voice and speech pattern or wearables (sleep and activity), and actively via user engagement through self-monitored data/self-assessment data (mood, sleep, stress, medicine adherence).

By collecting this data between physician visits, clinicians can see fluctuations in patients’ mental states, providing a more holistic representation of the patient’s functioning over time. The data hereby offer the opportunity for clinicians to predict relevant outcomes in mood disorders and can thus serve as a tool of triage enabling to provide timely and preventative support to the individuals in critical need.

This approach, also known as digital-enabled psychiatry, has gained considerable interest and been extensively researched over the past decade to offer more people access to high-quality health and social care.

To learn more, visit our Research section here or watch a video on the opportunity of digital-enabled psychiatry from the Week of Health and Innovation conference 2021 in Denmark.

References:

https://wfmh.global/2021-world-mental-health-global-awareness-campaign-world-mental-health-day-theme/

https://www.who.int/publications/i/item/9789240031029

https://www.who.int/campaigns/world-mental-health-day/2021

https://www.who.int/key-messages

[1] https://www.who.int/gho/publications/world_health_statistics/EN_WHS2012_Full.pdf

[2] The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011

[3] OECD – 2015

[4] Economist Intelligence Unit – 2015

A smartphone app that can help psychiatrists diagnose mental illness

A smartphone app that can help psychiatrists diagnose mental illness

by | Jul 27, 2020 | Anxiety, Bipolar, Blog, Customer Stories, Depression, Mental Illness, mHealth

“A smartphone app that can help psychiatrists diagnose mental illness” –  Peter Hagelund, a Monsenso user, speaks about his experience using the Monsenso mobile health solution to support his treatment, and how it has helped  him improve the communication with his psychiatrist.

Prior to using the Monsenso smartphone app, Peter and his psychiatrist followed the typical therapeutic setting, they would schedule an appointment every two-three weeks, and they would have a conversation to discuss Peter’s previous weeks.  Peter would usually say that he had been doing fine for each appointment, but sometimes he forgot important details that he wanted to discuss.

“It can be pretty tricky to remember, two weeks later [between appointments] how you actually felt that day. With the app it’s really easy to go back and see if your mood has been pretty stable over the last two months, or if you had had some ups and downs over a period,” says Peter Hagelund.

Now, instead of relying on Peter’s memory during the appointment, his psychiatrist can access his data and see how he has been doing, as it happened. He can view how much he has been sleeping, how much he exercises, how much he drinks, how much anxiety he has, and other relevant aspects to his treatment and his disorder.

“My psychiatrist now says things like You say you’ve been doing fine, but I can actually see that you’ve had a few ups and downs. I think the app helps him get a real view of how I have been doing,” says Peter Hagelund.

In his Danish documentary series “Jeg savner min sygdom” (which translates to “I miss my illness”), Peter Hagelund talks about his experience of getting the wrong diagnosis and how finally after six years he got the right diagnosis and treatment. 

In 2014, he was diagnosed with Bipolar Disorder Type 2.

During his whole life, he knew there was something different about him. He always struggled with depression and anxiety, and what eventually turned out to be hypomania. When he was 22, he had his first big episode of depression and began taking antidepressants. However, it took six more years before he was officially diagnosed with Bipolar Disorder Type 2.

He says that one of the trickiest things about having this diagnosis is that he does not experience the typical manic episode where a person feels over-energetic and nearly psychotic. Instead, he feels hypomanic, which means that he is socially well functioning. He is not psychotic. He just feels really well; the problem with this, was that he didn’t feel the need to inform his psychiatrist the fact that he was feeling too well. 

His psychiatrist found out that he had Bipolar Disorder was because he couldn’t come out of his depression. At first, he was diagnosed with depression and ADD. But these diagnoses didn’t seem to fit because he still had strong mood swings and a lot of anxiety. When he was diagnosed with Bipolar Disorder Type 2, it actually made sense to him. Suddenly, he could see why he had felt the way he had most of his life.

“I really believe that the Monsenso smartphone app could have helped my psychiatrist give me the right diagnosis at an earlier stage because the app helps me to keep track of my mood and to become more aware of how I feel. With the app, I have to pause and take a moment to think about how I’ve actually been doing before entering my answers. Keeping track of all this information has helped my treatment. My psychiatrist and I can plan better on how to avoid my future depressive or hypomanic episodes because we can clearly identify when I am having mood swings”. says Peter Hagelund.  

In August 2018, his documentary about living with Bipolar Disorder aired on national Danish television and the response was overwhelming. Many people contacted him, to thank him for talking about his illness. He made the documentary so other people who have this illness, do not feel ashamed of it.

“My hope is that in the future people are diagnosed at an earlier stage than I was and I truly believe the Monsenso app is one of the things that can help. I really hope that other psychiatrists and their patients will start using the app,” he added.

Click here to read this story in Danish.

BOOK A DEMO